Lu Y, Jiang Y, Prokaeva T, Connors LH & Costello CE. Oxidative post-translational modifications of an amyloidogenic immunoglobulin light chain protein. Int J Mass Spectrom. 2017 May. doi: 10.1016/j.ijms.2016.11.006. View in PubMed

Nguyen VP, Brauneis D, Kaku M, Sloan JM, Sarosiek S, Quillen K, Shelton AC, & Sanchorawala V. Neuralgic amyotrophy following high-dose melphalan and autologous peripheral blood stem cell transplantation for AL amyloidosis. Bone Marrow Transplant. 2017 Dec 21. doi: 10.1038/s41409-017-0048-6. View in PubMed

White MK, McCausland KL, Sanchorawala V, Guthrie SD, & Bayliss MS. Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples. Patient Relate Outcome Mass. 2017 Dec 7; 8: 157-167. doi: 10.2147/PROM.S146849. eCollection 2017. View in PubMed

Sanchorawala V, Sarosiek S, Sloan JM, Brauneis Dina, Migre ME, Mistark M, Santos S, Fennessey S, & Shelton AC. 507 Safety and tolerability of daratumumab in patients with relapsed light chain (AL) amyloidosis: preliminary results of a phase II study. ASH 59th Annual Meeting & Exposition. 2017 Dec 10. View in ASH

Chan GC, Koch CM & Connors LH. Serum proteomic variability associated with clinical phenotype in familial transthyretin amyloidosis (ATTRm). J Proteome Res. 2017 Sept 18. doi: 10.1021/acs.jproteome,7b004479. View in PubMed

Batalini F, Econimo L, Quillen K, Sloan JM, Sarosiek S, Brauneis D, Havasi A, Stern L, Dember L & Sanchorawala V. High dose melphalan and stem cell transplantation in patients on dialysis due to AL amyloidosis and monoclanal immunoglobulin deposition disease. Biol Blood Marrow Transplant. 2017 Aug 30. doi: 10.1016/j.bbmt.2017.08.031. View in PubMed

Sanchorawala V, McCausland KL, White MK, Bayliss MS, Guthrie SD, Lo S & Skinner M. A longitudinal evaluation of health-related quality of life in patients with AL amyloidosis: associations with health outcomes over time. British Journal of Haematology. 2017 Aug 29. doi: 10.1111/bjh.14889. View in Wiley

Arun M, Brauneis D, Doros G, Shelton AC, Sloan JM, Quillen K, Ruberg FL, Sanchorawala V & Varga C. The incidence of atrial fibrillation among patients with AL amyloidosis undergoing high-dose melphalan and stem cell transplantation: experience at a single institution. Bone Marrow Transplantation. 2017 July 24. doi: 10.1038/bmt.2017.148. View in PubMed

Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL & Merlini G. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory light-chain (AL) amyloidosis. Blood 2017. 2017 May 26. doi: 10.1182/blood-2017-03-771220. View in PubMed

Browning S, Quillen K, Sloan JM, Doros G, Sarosiek S & Sanchorawala V. Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation. Blood First Edition Paper. 2017 July 11. doi: 10.1182/blood-2017-06-788729. View in Blood Journal

Klimtchuk ES, Prokaeva TB, Spencer BH, Gursky O & Connors LH. In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis. Amyloid: The Journal of Protein Folding Disorders. Vol 24. 2017 Jun 20. doi: 10.1080/13506129.2017.1336996. View in Tandfonline

Arvanitis M, Simon S, Chan G, Fine D, Beardsley P, LaValley M, Jacobson D, Koch C, Berk JL, Connors LH & Ruberg FL. Retinol binding protein 4 (RBP4) concentration identifies V122I transthyretin cardiac amyloidosis. Amyloid: The Journal of Protein Folding Disorders. Vol 24. 2017 Apr 22. doi: 10.1080/13506129.2017.1295371. View in PubMed

Siddiqi, OK & Ruberg FL. Challenging the myths of cardiac amyloidosis. European Heart Journal 2017: 0, 1-4. 2017 Apr 24. doi: 10.1093/eurheartj/ehx043. View in Oup

Govender P, Keyes CM, Hankinson EA, O’Hara CJ, Sanchorawala V & Berk JL. Transbrochial biopsies safely diagnose amyloid lung disease. Amyloid: The Journal of Protein Folding Disorders. 2017 Apr 10. doi: 10.1080/13506129.2017.1301917. View in Tandfonline

Pulido V, Doros G, Berk JL & Sanchorawala V. The six-minute walk test in patients with AL amyloidosis: a single centre case series. Br J Haematol. 2017 Mar 24. doi: 10.1111/bjh.14586. View in PubMed

Ruberg FL. Cardiac amyloidosis: a zebra hiding in plain sight?. Circ Cardiovasc Imaging (3): e006186. 2017 March 10. doi: 10.1161/CIRCIMAGING.117.006186. View in PubMed

Arvanitis M, Koch CM, Chan GC, Torres-Arancivia C, LaValley MP, Jacobson DR, Berk JL, Connors LH & Ruberg FL. Identification of transthyretin cardiac amyloidosis using serum retinol-binding protein 4 and a clincal predication model. JAMA Cardiol 2(3): 305-3132017 March 1. doi: 10.1001/jamacardio.2016.5864. View in: Pubmed.

Chan GG, Koch CM & Connors LH. Blood proteomic profiling in inherited (ATTRm) and acquired (ATTRwt) forms of transthyretin-associated cardiac amyloidosis. J Proteome Res. 2017 Feb 14. doi: 10.1021/acs.jproteome.6b00998.  View in: PubMed

Pawar S, Haq M, Ruberg FL et al. Imaging options in cardiac amyloidosis: differentiating AL from ATTR. Curr Cardiovasc Imaging Rep, 2017, 2017 Feb 01.   doi:10.1007/s12410-017-9399-z                         View in: SpringerLink

Buxbaum JN & Ruberg FL. Transthyretin V122I (pV142I) cardiac amyloidosis: an age dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans. Genetics in Medicine, 2017, 2017 Jan 19.        View in: PubMed